Use App
Trending
News
Earnings
Newsletters
Advertise
All
DIA
0.26%
SPY
0.16%
QQQ
0.24%
Trending
HIMS
14.39%
AVT
3.43%
SLV
6.01%
APPS
7.00%
ARTV
113.72%
SEV
18.38%
GLD
2.48%
ORCL
6.79%
GTLB
5.41%
CVM
6.46%
HIMS
14.39%
AVT
3.43%
SLV
6.01%
APPS
7.00%
ARTV
113.72%
SEV
18.38%
GLD
2.48%
ORCL
6.79%
GTLB
5.41%
CVM
6.46%
home
Symbol
HALO
HALO
Halozyme Therapeutics Inc.
4,830
Loading...
Loading...
Feed
News
Sentiment
Earnings
Fundamentals
Info
News
all
press releases
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks
·
3h ago
Share to Feed
More News
Halozyme Rallies Almost 40% YTD: How Should You Play the Stock?
HALO's nearly 40% YTD surge is fueled by higher ENHANZE royalties. The Elektrofi deal also positions the company for long-term diversification.
Zacks
·
23h ago
Can Elektrofi Acquisition Drive Halozyme's Long-Term Growth?
HALO's impending acquisition of Elektrofi will add Hypercon tech to broaden its drug delivery platform and support long-term growth.
Zacks
·
9d ago
Are Medical Stocks Lagging Armata Pharmaceuticals (ARMP) This Year?
Here is how Armata Pharmaceuticals, Inc. (ARMP) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.
Zacks
·
11d ago
AbbVie Seeks FDA Nod for Tavapadon to Treat Parkinson's Disease
ABBV files for FDA approval of tavapadon, a once-daily oral Parkinson's drug backed by late-stage TEMPO studies.
Zacks
·
18d ago
Encompass Health Opens First Connecticut Rehab Hospital in Danbury
EHC opens its first Connecticut rehab hospital in Danbury, boosting its nationwide expansion and meeting rising demand for specialized care.
Zacks
·
21d ago
HRMY Stock Down as Fragile X Syndrome Study Fails to Meet Goal
Harmony Biosciences' shares plunge after ZYN002 failed in Fragile X, but Wakix sales and new epilepsy assets keep its pipeline moving forward.
Zacks
·
22d ago
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks
·
22d ago
BMY Reports Positive Data From a Late-Stage Multiple Myeloma Study
Bristol Myers reports positive phase III results for iberdomide in multiple myeloma, advancing its CELMoD pipeline and portfolio expansion.
Zacks
·
23d ago
Powell Warns of Valuation Risks: 5 High Earnings Yield Value Picks
Powell flags lofty valuations, but five high-earnings-yield stocks stand out as value picks in a cautious market.
Zacks
·
23d ago
Latest HALO News
View
Advertisement
|
Remove ads.
Advertisement
|
Remove ads.
Advertisement
|
Remove ads.
Watchlist
Trending
News
Explore
Community
Profile